Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio osservazionale, prospettico e multicentrico a lungo termine per raccogliere in una popolazione reale dati sul modello di trattamento di secukinumAb in pazienti adulti con idrosadenite suppurativa da moderata a grave. (ANIMA)

13 novembre 2026 aggiornato da: Novartis Pharmaceuticals

Studio osservazionale, prospettico, multicentrico a lungo termine per raccogliere in una popolazione reale dati sul modello di trattamento di secukinumAb in pazienti adulti con idrosadenite suppurativa (HS) da moderata a grave (ANIMA)

The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.

Panoramica dello studio

Stato

Attivo, non reclutante

Intervento / Trattamento

Descrizione dettagliata

The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.

In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

436

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Aachen, Germania, 52064
        • Novartis Investigative Site
      • Ahaus, Germania, 48683
        • Novartis Investigative Site
      • Annaberg-Buchholz, Germania, 09456
        • Novartis Investigative Site
      • Bad Steben, Germania, 95138
        • Novartis Investigative Site
      • Baden-Baden, Germania, 76530
        • Novartis Investigative Site
      • Berlin, Germania, 12159
        • Novartis Investigative Site
      • Berlin, Germania, 13595
        • Novartis Investigative Site
      • Bielefeld, Germania, 33647
        • Novartis Investigative Site
      • Bochum, Germania, 44791
        • Novartis Investigative Site
      • Bonn, Germania, 53105
        • Novartis Investigative Site
      • Brandenburg, Germania, 14776
        • Novartis Investigative Site
      • Bremen, Germania, 28359
        • Novartis Investigative Site
      • Buxtehude, Germania, 21614
        • Novartis Investigative Site
      • Bückeburg, Germania, 31675
        • Novartis Investigative Site
      • Chemnitz, Germania, 09117
        • Novartis Investigative Site
      • Chemnitz, Germania, 09113
        • Novartis Investigative Site
      • Cologne, Germania, 51065
        • Novartis Investigative Site
      • Delitzsch, Germania, 04509
        • Novartis Investigative Site
      • Dessau, Germania, 06847
        • Novartis Investigative Site
      • Dorsten, Germania, 46282
        • Novartis Investigative Site
      • Dortmund, Germania, 44137
        • Novartis Investigative Site
      • Dresden, Germania, 01309
        • Novartis Investigative Site
      • Düren, Germania, 52349
        • Novartis Investigative Site
      • Emsdetten, Germania, 48282
        • Novartis Investigative Site
      • Erlangen, Germania, 91054
        • Novartis Investigative Site
      • Falkenberg, Germania, 04895
        • Novartis Investigative Site
      • Falkensee, Germania, 14612
        • Novartis Investigative Site
      • Freising, Germania, 85354
        • Novartis Investigative Site
      • Geilenkirchen, Germania, 52511
        • Novartis Investigative Site
      • Gera, Germania, 07548
        • Novartis Investigative Site
      • Gernsbach, Germania, 76593
        • Novartis Investigative Site
      • Gladbeck, Germania, 45964
        • Novartis Investigative Site
      • Großenhain, Germania, 01558
        • Novartis Investigative Site
      • Hamburg, Germania, 20246
        • Novartis Investigative Site
      • Hamburg, Germania, 22143
        • Novartis Investigative Site
      • Hanover, Germania, 30159
        • Novartis Investigative Site
      • Haslach im Kinzigtal, Germania, 77716
        • Novartis Investigative Site
      • Hofgeismar, Germania, 34369
        • Novartis Investigative Site
      • Jena, Germania, 07743
        • Novartis Investigative Site
      • Jülich, Germania, 52428
        • Novartis Investigative Site
      • Karlsruhe, Germania, 76133
        • Novartis Investigative Site
      • Kempen, Germania, 47906
        • Novartis Investigative Site
      • Lübeck, Germania, 23538
        • Novartis Investigative Site
      • Magdeburg, Germania, 39120
        • Novartis Investigative Site
      • Magdeburg, Germania, 39104
        • Novartis Investigative Site
      • Mainz, Germania, 55116
        • Novartis Investigative Site
      • Marburg, Germania, 35043
        • Novartis Investigative Site
      • Minden, Germania, 32429
        • Novartis Investigative Site
      • Mönchengladbach, Germania, 41063
        • Novartis Investigative Site
      • Neu Wulmstorf, Germania, 21629
        • Novartis Investigative Site
      • Nuremberg, Germania, 90419
        • Novartis Investigative Site
      • Oberasbach, Germania, 90522
        • Novartis Investigative Site
      • Oelde, Germania, 59302
        • Novartis Investigative Site
      • Peitz, Germania, 03185
        • Novartis Investigative Site
      • Potsdam, Germania, 14469
        • Novartis Investigative Site
      • Remscheid, Germania, 42897
        • Novartis Investigative Site
      • Selters, Germania, 56242
        • Novartis Investigative Site
      • Simmern, Germania, 55469
        • Novartis Investigative Site
      • Soest, Germania, 59494
        • Novartis Investigative Site
      • Stolberg, Germania, 52222
        • Novartis Investigative Site
      • Unna, Germania, 59423
        • Novartis Investigative Site
      • Wittlich, Germania, 54316
        • Novartis Investigative Site
      • Wuppertal, Germania, 42103
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79068
        • Novartis Investigative Site
      • Rheinstetten, Baden-Wurttemberg, Germania, 76287
        • Novartis Investigative Site
    • Bavaria
      • Haßfurt, Bavaria, Germania, 97437
        • Novartis Investigative Site
      • Kulmbach, Bavaria, Germania, 95326
        • Novartis Investigative Site
      • Lauf an der Pegnitz, Bavaria, Germania, 91207
        • Novartis Investigative Site
      • Nuremberg, Bavaria, Germania, 90402
        • Novartis Investigative Site
    • Brandenburg
      • Panketal, Brandenburg, Germania, 16341
        • Novartis Investigative Site
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Germania, 22549
        • Novartis Investigative Site
    • Lower Saxony
      • Lingen, Lower Saxony, Germania, 49809
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Bergen auf Rügen, Mecklenburg-Vorpommern, Germania, 18528
        • Novartis Investigative Site
      • Kröpelin, Mecklenburg-Vorpommern, Germania, 18236
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Krefeld, North Rhine-Westphalia, Germania, 47798
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Germania, 55128
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Germania, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, Germania, 04207
        • Novartis Investigative Site
      • Leipzig, Saxony, Germania, 04289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Wittenberg, Saxony-Anhalt, Germania, 06886
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 99 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Descrizione

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  1. Patients who provide written informed consent to participate in the study
  2. Male and female patients with ≥18 years of age
  3. Diagnosis of clinically unequivocal moderate to severe HS
  4. Patients for whom a therapy with secukinumab is medically indicated
  5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
  6. Treatment with secukinumab according to the latest version of SmPC
  7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

  1. Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
  2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
  4. Previous exposure to IL-17 inhibitors
  5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
secukinumab

Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of patients receiving up-titration
Lasso di tempo: Up to 24 months

Proportion of patients receiving up-titration (q4w-to-q2w)

Up to 24 months
Proportion of patients receiving down-titration
Lasso di tempo: Up to 24 months

Proportion of patients receiving down-titration (q2w-to-q4w)

Up to 24 months
Time to up-titration and down-titration
Lasso di tempo: Up to 2 years

Time to up-titration and down-titration

Up to 2 years
Duration of q4w treatment with secukinumab after dose reduction
Lasso di tempo: Up to 2 years

Duration of q4w treatment with secukinumab after dose reduction

Up to 2 years
Proportion of patients who receive more than one up-and/or down titration
Lasso di tempo: Up to 24 months

Proportion of patients who receive more than one up-and/or down titration

Up to 24 months
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Lasso di tempo: Up to 2 years

Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

Up to 2 years
Number and type of surgical interventions
Lasso di tempo: Up to 2 years

Number and type of surgical interventions

  • minor and major surgical excision;
  • inpatient, outpatient
Up to 2 years
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Lasso di tempo: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Lasso di tempo: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Lasso di tempo: Up to 24 months

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school.

Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Up to 24 months
Mean reduction of Abscesses and inflammatory nodules (AN) count
Lasso di tempo: Up to 24 months

Mean reduction of Abscesses and inflammatory nodules (AN) count

Up to 24 months
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Lasso di tempo: Up to 24 months

The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form.

Up to 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 agosto 2023

Completamento primario (Stimato)

31 marzo 2027

Completamento dello studio (Stimato)

31 marzo 2027

Date di iscrizione allo studio

Primo inviato

16 giugno 2023

Primo inviato che soddisfa i criteri di controllo qualità

26 giugno 2023

Primo Inserito (Effettivo)

28 giugno 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi